title: TO901317 regulating apolipoprotein M expression mediates via the farnesoid X receptor pathway in Caco-2 cells.
abstract: BACKGROUND
  Apolipoprotein M (apoM) may have potential antiatherosclerotic properties. It has been reported that apoM expression could be regulated by many intracellar and extracellar factors. In the present study we further investigated regulation of apoM expression in Caco-2 cells stimulated by a liver X receptor (LXR) agonist, TO901317.
  
  
  METHODS
  Caco-2 cells were cultured in the presence of either TO901317, farnesoid X receptor (FXR) antagonist guggulsterone or TO901317 together with guggulsterone at different concentrations for 24 hrs. The mRNA levels of ATP-binding cassette transporter A1 (ABCA1), apoA1, apoM, liver receptor homologue-1 (LRH-1) and short heterodimer partner 1 (SHP1) were determined by real-time RT-PCR.
  
  
  RESULTS
  When Caco-2 cell cultured with TO901317 alone, the mRNA levels of ABCA1, apoA1, apoM, LRH-1 and SHP1 were significantly increased with dose-dependent manners (p < 0.05), whereas when the cells cultured with guggulsterone alone, the mRNA levels of apoM, SHP1 and LRH-1 (p < 0.05) were strongly inhibited. Moreover, guggulsterone could abolish the TO901317 enhanced mRNA levels of apoA1 apoM, SHP1 and LRH-1.
  
  
  CONCLUSIONS
  The present study demonstrated that LXR agonist TO901317 induced apoM expression in Caco-2 cells might be mediated via the LXR/FXR pathway.
authors: Department of Cardiothoracic Surgery, Third Affiliated Hospital of Suzhou University, Changzhou 213003, P.R. China.
authors: Chunhua
authors: C
authors: Zhu
authors: Dongmei
authors: D
authors: Di
authors: Xiaoying
authors: X
authors: Zhang
authors: Guanghua
authors: G
authors: Luo
authors: Zongchun
authors: Z
authors: Wang
authors: Jiang
authors: J
authors: Wei
authors: Yuanping
authors: Y
authors: Shi
authors: Maria
authors: M
authors: Berggren-Söderlund
authors: Peter
authors: P
authors: Nilsson-Ehle
authors: Ning
authors: N
authors: Xu
mesh_terms: D064286:ATP Binding Cassette Transporter 1; D018528:ATP-Binding Cassette Transporters / Q000235:genetics / Q000378:metabolism; D016632:Apolipoprotein A-I / Q000235:genetics / Q000378:metabolism; D001053:Apolipoproteins / Q000235:genetics / Q000378:metabolism*; D000075243:Apolipoproteins M; D018938:Caco-2 Cells; D015870:Gene Expression; D005786:Gene Expression Regulation / Q000187:drug effects*; D006801:Humans; D006845:Hydrocarbons, Fluorinated / Q000494:pharmacology*; D054834:Lipocalins / Q000235:genetics / Q000378:metabolism*; D000071518:Liver X Receptors; D057093:Orphan Nuclear Receptors / Q000819:agonists* / Q000378:metabolism; D011282:Pregnenediones / Q000494:pharmacology*; D018160:Receptors, Cytoplasmic and Nuclear / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D013449:Sulfonamides / Q000494:pharmacology*; D000099150:Receptor, Farnesoid X-Activated; D005466:Fluorocarbons; D000096926:Benzenesulfonamides
chemical_list: D064286:ATP Binding Cassette Transporter 1; D018528:ATP-Binding Cassette Transporters; D016632:Apolipoprotein A-I; D001053:Apolipoproteins; D000075243:Apolipoproteins M; D006845:Hydrocarbons, Fluorinated; D054834:Lipocalins; D000071518:Liver X Receptors; D057093:Orphan Nuclear Receptors; D011282:Pregnenediones; D018160:Receptors, Cytoplasmic and Nuclear; D013449:Sulfonamides; D000099150:Receptor, Farnesoid X-Activated; C577836:ABCA1 protein, human; C505693:APOA1 protein, human; C400523:APOM protein, human; C082631:NR5A2 protein, human; C423915:T0901317; D005466:Fluorocarbons; D000096926:Benzenesulfonamides; C099713:nuclear receptor subfamily 0, group B, member 2; C023617:pregna-4,17-diene-3,16-dione